# Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

> **NCT07096193** · PHASE1,PHASE2 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 107 (estimated)

## Conditions studied

- Chronic Hepatitis Delta

## Interventions

- **DRUG:** GS-4321
- **DRUG:** GS-4321 Placebo
- **DRUG:** GS-4321

## Key facts

- **NCT ID:** NCT07096193
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-31
- **Primary completion:** 2029-02
- **Final completion:** 2029-02
- **Target enrollment:** 107 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07096193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07096193, "Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07096193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*